Skip Over Navigation Links


TRND Projects

NCATS selects TRND projects based on their potential to move forward into human trials and transform patient care for rare and neglected diseases. Each project has the potential for success and ability to teach important lessons about rare and neglected disease drug development. Click on the links below to view active and completed TRND projects. Read the TRND fact sheet.

Active Projects

Completed Projects

New TRND Projects

Mosquito on finger

On Oct. 15, 2014, NCATS announced three new pre-clinical drug development projects aimed at finding treatments for malaria, Lassa fever, and two rare blood disorders: beta-thalassemia and sickle cell disease. Read the announcement.

Industry Acquires First Drug Candidate from TRND Program

Red blood cells showing sickling from sickle cell disease.

On July 9, 2014, NIH announced that biopharmaceutical company Baxter International has acquired a drug candidate developed by NCATS' Therapeutics for Rare and Neglected Diseases (TRND) researchers and collaborators. The small molecule, Aes-103, is designed to treat sickle cell disease, a genetic blood disorder that affects millions worldwide, including approximately 100,000 people in the United States — among them, 1 in 500 African-Americans.

NIH News Release

NCATS Director’s Message

Baxter International News Release

TRND Aes-103 Project Page

TRND Fact Sheet